Palatin Technologies (NYSE:PTN) Now Covered by Analysts at assumed coverage on shares of Palatin Technologies (NYSE:PTNGet Rating) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Palatin Technologies Stock Performance

Shares of Palatin Technologies stock opened at $0.27 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.53 and a quick ratio of 3.44. The business’s 50 day moving average is $0.31. The firm has a market cap of $62.56 million, a PE ratio of -1.69 and a beta of 1.10. Palatin Technologies has a twelve month low of $0.26 and a twelve month high of $0.96.

Palatin Technologies (NYSE:PTNGet Rating) last announced its quarterly earnings results on Tuesday, May 17th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.58 million. Palatin Technologies had a negative return on equity of 95.87% and a negative net margin of 4,280.18%. Sell-side analysts predict that Palatin Technologies will post -0.14 earnings per share for the current year.

Palatin Technologies Company Profile

(Get Rating)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Featured Stories

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.